Discontinuation and reinstitution of medications during the perioperative period

American Journal of Health-System Pharmacy

Volumn 61, Issue 9, 2004, Pages 899-914

  Pass, Steven E ^a,b   Simpson, Robert W ^c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c UH ^*

Author keywords

Anesthetics; Anticoagulants; Cardiac drugs; Central nervous system drugs; Drug interactions; Drug withdrawal; Hypotensive agents; Plants; Platelet aggregation inhibitors; Psychotherapeutic agents; Surgery; Thrombolytic agents; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANESTHETIC AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIOVASCULAR AGENT; CENTRAL NERVOUS SYSTEM AGENTS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESMOLOL; HEPARIN; HERBACEOUS AGENT; HYPERTENSIVE FACTOR; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VERAPAMIL; WARFARIN; DRUG;

ANXIETY DISORDER; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CHRONOTROPISM; CLINICAL FEATURE; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONVULSION; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDICATION; DRUG INFUSION; DRUG INHIBITION; DRUG POTENTIATION; DRUG SAFETY; ECCHYMOSIS; FORWARD HEART FAILURE; GASTROINTESTINAL MOTILITY; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERPYREXIA; HYPERTENSION; HYPOTENSION; INJECTION SITE; INOTROPISM; ISCHEMIA; LIVER TOXICITY; LONG TERM CARE; MYOCLONUS; NONHUMAN; PERIOPERATIVE PERIOD; PEROPERATIVE COMPLICATION; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE CARE; PRIORITY JOURNAL; PROFESSIONAL STANDARD; PROTHROMBIN TIME; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; SINUS BRADYCARDIA; SPINAL CORD HEMORRHAGE; SUDDEN DEATH; SUPRAVENTRICULAR PREMATURE BEAT; SYSTEMIC VASCULAR RESISTANCE; TACHYCARDIA; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VASODILATATION; WITHDRAWAL SYNDROME; CLASSIFICATION; CONTINUING EDUCATION; DRUG ADMINISTRATION; HERBAL MEDICINE; PHARMACIST; UNITED STATES;

DRUG ADMINISTRATION SCHEDULE; EDUCATION, CONTINUING; HUMANS; MEDICINE, HERBAL; PERIOPERATIVE CARE; PHARMACEUTICAL PREPARATIONS; PHARMACISTS; PROFESSIONAL ROLE; UNITED STATES;

EID: 8344260709     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/61.9.899     Document Type: Review

References (143)

1. Centers for Disease Control and Prevention. National hospital discharge survey: 2000 annual summary. www.cdc.gov/nchs/data/series/sr_13/sr13_153.pdf (accessed 2003 Jun 24).
2. Duthie DJ, Montgomery JN, Spence AA et al. Concurrent drug therapy in patients undergoing surgery. Anaesthesia. 1987; 42:305-11.
3. Bond CA, Raehl CL, Franke T. Medication errors in United States hospitals. Pharmacotherapy. 2001; 21:1023-36.
4. Desborough JP. The stress response to trauma and surgery. Br J Anaesth. 2000; 85:109-17.
5. Thompson JS. The intestinal response to critical illness. Am J Gastroenterol. 1995; 90:190-200.
6. Heyland DK, Tougas G, King D et al. Impaired gastric empting in mechanically ventilated, critically ill patients. Intensive Care Med. 1996; 22:1339-44.
7. Elfant AB, Levine SM, Peikin SR et al. Bioavailability of medication delivered via nasogastric tube is decreased in the immediate postoperative period. Am J Surg. 1995; 169:430-2.
8. Kennedy JM, van Rij AM, Spears GF et al. Polypharmacy in a general surgical unit and consequences of drug withdrawal. Br J Clin Pharmacol. 2000; 49:353-62.
9. Kim Y, Danchak M, Macnamara TE. Drug interaction and anesthesia. Clin Ther. 1987; 9:342-3.
10. Smith MS, Muir H, Hall R. Perioperative management of drug therapy: clinical considerations. Drugs. 1996; 51:238-59.
11. Frishman WH. Beta-adrenergic blocker withdrawal. Am J Cardiol. 1987; 59:26F-32F.
12. Hart GR, Anderson RJ. Withdrawal syndromes and the cessation of antihypertensive therapy. Arch Intern Med. 1981; 141:1125-7.
13. Psaty BM, Koepsell TD, Wagner EH et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta-blockers. JAMA. 1990; 263:1653-7.
14. Goldman L. Noncardiac surgery in patients receiving propranolol: case reports and recommended approach. Arch Intern Med. 1981; 141:193-6.
15. Langou RA, Wiles JC, Peduzzi PN et al. Incidence and mortality of perioperative myocardial infarction in patients undergoing coronary artery bypass grafting. Circulation. 1977; 56(3 suppl): II54-8.
16. Stone JG, Foëx P, Sear JW et al. Myocardial ischemia in untreated hypertensive patients: effect of a single small oral dose of a beta-adrenergic blocking agent. Anesthesiology. 1988; 68:495-500.
17. Yeager RA, Moneta GL, Edwards JM et al. Reducing perioperative myocardial infarction following vascular surgery: the potential role of beta-blockade. Arch Surg. 1995; 130:869-72.
18. Wallace A, Layug B, Tateo I et al. Prophylactic atenolol reduces postoperative myocardial ischemia. Anesthesiology. 1998; 88:7-17.
19. Pasternack PF, Grossi EA, Baumann FG et al. Beta blockade to decrease silent myocardial ischemia during peripheral vascular surgery. Am J Surg. 1989; 158:113-6.
20. Raby KE, Brull SJ, Timimi F et al. The effect of heart rate control on myocardial ischemia among high-risk patients after vascular surgery. Anesth Analg. 1999; 88:477-82.
21. Mangano DT, Layug EL, Wallace A et al. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 1996; 335:1713-20.
22. Reves JG, Kissin I, Lell WA et al. Calcium entry blockers: uses and implications for anesthesiologists. Anesthesiology. 1982; 57:504-18.
23. Merin RG. Calcium channel blocking drugs and anesthetics: is the drug interaction beneficial or detrimental? Anesthesiology. 1987; 66:111-3.
24. Schlanz KD, Myre SA, Bottorff MB. Pharmacokinetic interactions with calcium channel antagonists (part II). Clin Pharmacokinet. 1991; 21:448-60.
25. Lewis GB. Haemodynamic disturbances during anaesthesia in a patient receiving verapamil. Br J Anaesth. 1987; 59:1337. Letter.
26. Moller IW. Cardiac arrest following i.v. verapamil combined with halothane anaesthesia. Br J Anaesth. 1987; 59:522-3. Letter.
27. Lyons TE. Preoperative nifedipine management. Anesth Analg. 1983; 62:1138. Letter.
28. Gorven AM, Cooper GM, Prys-Roberts C. Haemodynamic disturbances during anaesthesia in a patient receiving calcium channel blockers. Br J Anaesth. 1986; 58:357-60.
29. Hess W, Meyer C. Haemodynamic effects of nifedipine in patients undergoing coronary artery bypass surgery. Acta Anaesthesiol Scand. 1986; 30:614-9.
30. Freis ES, Lappas DG. Chronic administration of calcium entry blockers and the cardiovascular responses to high doses of fentanyl in man. Anesthesiology. 1982; 57:A295. Abstract.
31. Kapur PA, Norel EJ, Dajee H et al. Haemodynamic effects of verapamil administration after large doses of fentanyl in man. Can Anaesth Soc J. 1986; 33:138-44.
32. Henling CE, Slogoff S, Kodali SV et al. Heart block after coronary artery bypass - effect of chronic administration of calcium-entry blockers and beta-blockers. Anesth Analg. 1984; 63:515-20.
33. Colson P, Ryckwaert F, Coriat P. Renin angiotensin system antagonists and anesthesia. Anesth Analg. 1999; 89:1143-55.
34. Colson P, Saussine M, Seguin JR et al. Hemodynamic effects of anesthesia in patients chronically treated with angiotensin-converting enzyme inhibitors. Anesth Analg. 1992; 74:805-8.
35. Ryckwaert F, Colson P. Hemodynamic effects of anesthesia in patients with ischemic heart failure chronically treated with angiotensin-converting enzyme inhibitors. Anesth Analg. 1997; 84:945-9.
36. Coriat P, Richer C, Douraki T et al. Influence of chronic angiotensin-converting enzyme inhibition on anesthetic induction. Anesthesiology. 1994; 81:299-307.
37. Pigott DW, Nagle C, Allman K et al. Effect of omitting regular ACE inhibitor medication before cardiac surgery on haemodynamic variables and vasoactive drug requirements. Br J Anaesth. 1999; 83:715-20.
38. Tohmo H, Karanko M. Angiotensin-converting enzyme inhibitors and anaesthesia. Acta Anaesthesiol Scand. 1996; 40:132-3. Letter.
39. Brabant SM, Bertrand M, Eyraud D et al. The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists. Anesth Analg. 1999; 89:1388-92.
40. Bertrand M, Godet G, Meersschaert K et al. Should the angiotensin II antagonists be discontinued before surgery? Anesth Analg. 2001; 92:26-30.
41. McEvoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists; 2003.
42. Lexi-Drugs Platinum, palm version. Hudson, OH: Lexi-Comp; 2003.
43. Altace package insert. Kansas City, MO: Aventis Pharmaceuticals; 2003 Feb.
44. Accupril package insert. New York: Parke-Davis; 2002 Jan.
45. Aceon package insert. Marietta, GA: Solvay Pharmaceuticals; 2002 Feb.
46. Perkins MW, Dasta JF, Reilley TE et al. Intraoperative complications in patients receiving amiodarone: characteristics and risk factors. DICP. 1989; 23:757-63.
47. Singh BN, Vaughan-Williams EM. The effects of amiodarone, a new anti-anginal drug on cardiac muscle. Br J Pharmacol. 1970; 39:657-67.
48. Liberman BA, Teasdale SJ. Anesthesia and amiodarone. Can Anaesth Soc J. 1985; 32:629-38.
49. Meulendyk J. Anesthetic considerations with amiodarone: report of a case. J Am Osteopath Assoc. 1984; 83:585-8.
50. Gallagher JD, Lieberman RW, Meranze J et al. Amiodarone-induced complications during coronary artery surgery. Anesthesiology. 1981; 55:186-8.
51. Feinberg BI, LaMantia KR, Levy WJ. Amiodarone and general anesthesia: a retrospective analysis. Anesth Analg. 1986; 65:S49.
52. MacKinnon G, Landymore R, Marble A. Should oral amiodarone be used for sustained ventricular tachycardia in patients requiring open-heart surgery? Can J Surg. 1983; 26:355-7.
53. Elliott PL, Schauble JF, Rogers MC et al. Risk of decompensation during anesthesia in presence of amiodarone. Circulation. 1983; 68(suppl III):III-280.
54. Chassard D, George M, Guiraud M et al. Relationship between preoperative amiodarone treatment and complications observed during anesthesia for valvular cardiac surgery. Can J Anaesth. 1990; 37:251-4.
55. Cordarone package insert. Philadelphia: Wyeth-Laboratories; 2002 Aug.
56. Teasdale S, Downar E. Amiodarone and anesthesia. Can J Anaesth. 1990; 37:151-5.
57. Geerts WH, Heit JA, Clagett GP et al. Prevention of venous thromboembolism. Chest. 2001; 119:132S-75S.
58. Cygan R, Waitzkin H. Stopping and restarting medications in the perioperative period. J Gen Intern Med. 1987; 2:270-83.
59. Lazio BE, Simard JM. Anticoagulation in neurosurgical patients. Neurosurgery. 1999; 45:838-47.
60. Wijdicks EF, Schievink WI, Brown RD et al. The dilemma of discontinuation of anticoagulation therapy for patients with intracranial hemorrhage and mechanical heart valves. Neurosurgery. 1998; 42:769-73.
61. Kawamata T, Takeshita M, Kubo O et al. Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol. 1995; 44:438-42.
62. Eisen GM, Baron TH, Dominitz JA et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc. 2002; 55:775-9.
63. Dunn AS, Turpie AG. Perioperative management of patients receiving oral anticoagulants: a systematic review. Arch Intern Med. 2003; 163:901-8.
64. Hall DL, Steen WH, Drummond JW. Anticoagulants and cataract surgery. Ann Ophthalmol. 1980; 12:759-80.
65. McMahan LB. Anticoagulants and cataract surgery. J Cataract Refract Surg. 1988; 14:569-71.
66. Gainey SP, Robertson DM, Fay W et al. Ocular surgery on patients receiving long-term warfarin therapy. Am J Ophthalmol. 1989; 108:142-6.
67. Billingsley EM, Maloney ME. Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents. A prospective study. Dermatol Surg. 1997; 23:381-3.
68. Otley CC, Fewkes JL, Frank W et al. Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs. Arch Dermatol. 1996; 132:161-6.
69. Alcalay J. Cutaneous surgery in patients receiving warfarin therapy. Dermatol Surg. 2001; 27:756-8.
70. Alam M, Goldberg LH. Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy. Dermatol Surg. 2002; 28:992-8.
71. Schanbacher CF, Bennett RG. Postoperative stroke after stopping warfarin for cutaneous surgery. Dermatol Surg. 2000; 26:785-9.
72. Lumpkin MM. FDA public health advisory. Anesthesiology. 1998; 88:27A-8A.
73. Ansell J, Hirsh J, Dalen J et al. Managing oral anticoagulant therapy. Chest. 2001; 119:22S-38S.
74. Johnson J, Turpie AG. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin. Thromb Haemost. 1999; 82:62-3. Abstract.
75. Spandorfer JM, Lynch S, Weitz HH et al. Use of enoxaparin for the chronically anticoagulated patient before and after procedures. Am J Cardiol. 1999; 84:478-80.
76. Tinmouth AH, Morrow BH, Cruickshank MK et al. Dalteparin as periprocedure anticoagulation for patients on warfarin and at high risk of thrombosis. Ann Pharmacother. 2001; 35:669-74.
77. Crowther MA, Douketis JD, Schnurr T et al. Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med. 2002; 137:251-4.
78. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997; 336:1506-11.
79. Mercado DL, Petty BG. Perioperative medication management. Med Clin North Am. 2003; 87:41-57.
80. Lovenox package insert. Bridgewater, NJ: Aventis Pharmaceuticals; 2003 Jul.
81. Patrono C, Coller B, Dalen JE et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001; 119:39S-63S.
82. Quinn MJ, Fitzgerald DJ. Ticlopidine and clopidogrel. Circulation. 1999; 100:1667-72.
83. Burch JW, Majerus PW. The role of prostaglandins in platelet function. Semin Hematol. 1979; 16:196-207.
84. Ferraris VA, Ferraris SP, Joseph O et al. Aspirin and postoperative bleeding after coronary artery bypass grafting. Ann Surg. 2002; 235:820-7.
85. Ferraris VA, Ferraris SP, Lough FC et al. Preoperative aspirin ingestion increases operative blood loss after coronary artery bypass grafting. Ann Thorac Surg. 1988; 45:71-4.
86. Puga FJ. Risk of preoperative aspirin in patients undergoing coronary artery bypass surgery. J Am Coll Cardiol. 1990; 15:21-2. Editorial.
87. Kitchen L, Erichson RB, Sideropoulos H. Effect of drug-induced platelet dysfunction on surgical bleeding. Am J Surg. 1982; 143:215-7.
88. Sethi GK, Copeland JG, Goldman S et al. Implications of preoperative administration of aspirin in patients undergoing coronary artery bypass grafting. Department of Veterans Affairs Cooperative Study on Antiplatelet Therapy. J Am Coll Cardiol. 1990; 15:15-20.
89. Caliendo G, Bradbury K, Mehl B. Ticlopidine, bleeding, and surgery. Mt Sinai J Med. 1994; 61:372-3.
90. Criado A, Juffe A, Carmona J et al. Ticlopidine as a hemorrhagic risk factor in coronary surgery. Drug Intell Clin Pharm. 1985; 19:673-6.
91. Yende S, Wunderink RG. Effect of clopidogrel on bleeding after coronary artery bypass surgery. Crit Care Med. 2001; 29:2271-5.
92. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. J Thromb Thrombolysis. 2002; 13:97-103.
93. Spell NO 3rd. Stopping and restarting medications in the perioperative period. Med Clin North Am. 2001; 85:1117-28.
94. Leese PT, Hubbard RC, Karim A et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000; 40:124-32.
95. Ticlid package insert. Nutley, NJ: Roche Laboratories; 2001 Mar.
96. Vioxx package insert. Whitehouse Station, NJ: Merck; 2003 Apr.
97. Scher CS, Anwar M. The self-reporting of psychiatric medications in patients scheduled for elective surgery. J Clin Anesth. 1999; 11:619-21.
98. Haddad PM. Antidepressant discontinuation syndromes. Drug Saf. 2001; 24:183-97.
99. Wolfe RM. Antidepressant withdrawal reactions. Am Fam Physician. 1997; 56:455-62.
100. Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997; 58(suppl 7):11-5.
101. El-Ganzouri AR, Ivankovich AD, Braverman B et al. Monoamine oxidase inhibitors: should they be discontinued preoperatively? Anesth Analg. 1985; 64:592-6.
102. Stack CG, Rogers P, Linter SP. Monoamine oxidase inhibitors and anaesthesia: a review. Br J Anaesth. 1988; 60:222-7.
103. Elis J, Laurence DR, Mattie H et al. Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure. Br Med J. 1967; 2:75-8.
104. Wells DG, Bjorksten AR. Monoamine oxidase inhibitors revisited. Can J Anaesth. 1989; 36:64-74.
105. Malan TP Jr, Nolan PE, Lichtenthal PR et al. Severe, refractory hypotension during anesthesia in a patient on chronic clomipramine therapy. Anesthesiology. 2001; 95:264-6.
106. Ramanathan KB, Davidson C. Cardiac arrhythmia and imiprimine therapy. Br Med J. 1975; 1:661-2.
107. Sprung J, Schoenwald PK, Levy P et al. Treating intraoperative hypotension in a patient on long-term tricyclic antidepressants: a case of aborted aortic surgery. Anesthesiology. 1997; 86:990-2.
108. Veerman M, Goodwin SR. Drug interactions. In: Kirby RR, Gravenstein N, Lobato EB et al., eds. Clinical anesthesia practice. 2nd ed. Philadelphia: W. B. Saunders; 2002:683-706.
109. Jahr JS, Pisto JD, Gitlin MC et al. The serotonin syndrome in a patient receiving sertraline after an ankle block. Anesth Analg. 1994; 79:189-91.
110. Kam PC, Chang GM. Selective serotonin reuptake inhibitors: pharmacology and clinical implications in anaesthesia and critical care medicine. Anaesthesia. 1997; 52:982-8.
111. Sternbach H. The serotonin syndrome. Am J Psychiatry. 1991; 148:705-13.
112. Busto U, Sellers EM. Pharmacologic aspects of benzodiazepine tolerance and dependence. J Subst Abuse Treat. 1991; 8:29-33.
113. Ashton H. Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat. 1991; 8:19-28.
114. Browne JL, Hauge KJ. A review of alprazolam withdrawal. Drug Intell Clin Pharm. 1986; 20:837-41.
115. Zipursky RB, Baker RW, Zimmer B. Alprazolam withdrawal delirium unresponsive to diazepam: case report. J Clin Psychiatry. 1985; 46:344-5.
116. Kantor SJ. A difficult alprazolam withdrawal. J Clin Psychopharmacol. 1986; 6:124-5. Letter.
117. Votolato NA, Batcha KJ, Olson SC. Alprazolam withdrawal. Drug Intell Clin Pharm. 1987; 21:754-5. Letter.
118. Freda JJ, Bush HL, Barie PS. Alprazolam withdrawal in a critically ill patient. Crit Care Med. 1992; 20:545-6.
119. Eisenberg DM, Davis RB, Ettner SL et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA. 1998; 280:1569-75.
120. Crowe S, Fitzpatrick G, Jamaluddin MF. Use of herbal medicines in ambulatory surgical patients. Anaesthesia. 2002; 57:203-4. Letter.
121. Blendon RJ, DesRoches CM, Benson JM et al. Americans' views on the use and regulation of dietary supplements. Arch Intern Med. 2001; 161:805-10.
122. Kaye AD, Clarke RC, Sabar R et al. Herbal medicines: current trends in anesthesiology practice - a hospital survey. J Clin Anesth. 2000; 12:468-71.
123. Tsen LC, Segal S, Pothier M et al. Alternative medicine use in presurgical patients. Anesthesiology. 2000; 93:148-51.
124. Skinner CM, Rangasami J. Preoperative use of herbal medicines: a patient survey. Br J Anaesth. 2002; 89:792-5.
125. Hodges PJ, Kam PC. The peri-operative implications of herbal medicines. Anaesthesia. 2002; 57:889-99.
126. Ang-Lee MK, Moss J, Yuan CS. Herbal medicines and perioperative care. JAMA. 2001; 286:208-16.
127. Sabar R, Kaye AD, Frost EA. Perioperative considerations for the patient taking herbal medicines. Heart Dis. 2001; 3:87-96.
128. Miller LG. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med. 1998; 158:2200-11.
129. Chung KF, Dent G, McCusker M et al. Effect of a ginkgolide mixture (BN 52063) in antagonising skin and platelet responses to platelet activating factor in man. Lancet. 1987; 1:248-51.
130. Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg. 2001; 67:33-5.
131. Grant KL, Lutz RB. Ginger. Am J Health-Syst Pharm. 2000; 57:945-7.
132. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother. 2000; 34:1478-82.
133. Pepping J. Kava: Piper methysticum. Am J Health-Syst Pharm. 1999; 56:957-8, 960.
134. Plushner SL. Valerian: Valeriana officinalis. Am J Health-Syst Pharm. 2000; 57:328,333,335.
135. Pepping J. St. John's wort: Hypericum perforatum. Am J Health-Syst Pharm. 1999; 56:329-30.
136. Leak JA. Herbal medicines: what do we need to know? www.asahq.org/ newsletters/2000/02_00/herbal0200.htm (accessed 2003 Jun 24).
137. Bond CA, Raehl CL, Franke T. Clinical pharmacy services and hospital mortality rates. Pharmacotherapy. 1999; 19:556-64.
138. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282:267-70.
139. Hassan Y, Aziz NA, Awang J et al. An analysis of clinical pharmacist interventions in an intensive care unit. J Clin Pharm Ther. 1992; 17:347-51.
140. Smythe MA, Shah PP, Spiteri TL et al. Pharmaceutical care in medical progressive care patients. Ann Pharmacother. 1998; 32:294-9.
141. Bjornson DC, Hiner WO Jr, Potyk RP et al. Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm. 1993; 50:1875-84.
142. Papadopoulos J, Rebuck JA, Lober C et al. The critical care pharmacist: an essential intensive care practitioner. Pharmacotherapy. 2002; 22:1484-8.
143. Kucukarslan SN, Peters M, Mlynarek M et al. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003; 163:2014-8.